| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | IACOBONI, GLORIA |
| dc.contributor.author | Rejeski, Kai |
| dc.contributor.author | Villacampa Javierre, Guillermo |
| dc.contributor.author | van Doesum, Jaap |
| dc.contributor.author | CHIAPPELLA, ANNALISA |
| dc.contributor.author | Bonifazi, Francesca |
| dc.contributor.author | Camacho-Arteaga, Lina |
| dc.contributor.author | Marin Niebla, Ana |
| dc.contributor.author | Barba, Pere |
| dc.date.accessioned | 2023-05-24T11:38:24Z |
| dc.date.available | 2023-05-24T11:38:24Z |
| dc.date.issued | 2022-06-28 |
| dc.identifier.citation | Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022 Jun 28;6(12):3606–10. |
| dc.identifier.issn | 2473-9529 |
| dc.identifier.uri | https://hdl.handle.net/11351/9613 |
| dc.description | Tractament; Limfoma de cèl·lules del mantell; Recaiguda |
| dc.language.iso | eng |
| dc.publisher | American Society of Hematology |
| dc.relation.ispartofseries | Blood Advances;6(12) |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Teràpia cel·lular |
| dc.subject | Limfomes - Tractament |
| dc.subject.mesh | Lymphoma, Mantle-Cell |
| dc.subject.mesh | /drug therapy |
| dc.subject.mesh | Immunotherapy, Adoptive |
| dc.title | Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1182/bloodadvances.2021006922 |
| dc.subject.decs | linfoma de células del manto |
| dc.subject.decs | /farmacoterapia |
| dc.subject.decs | inmunoterapia adoptiva |
| dc.relation.publishversion | https://doi.org/10.1182/bloodadvances.2021006922 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Iacoboni G, Marín-Niebla A, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Rejeski K] Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. [Villacampa G] Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. The Institute of Cancer Research, London, United Kingdom. [van Doesum JA] Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. [Chiappella A] Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy. [Bonifazi F] IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seragnoli”, Bologna, Italy. [Camacho-Arteaga L] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain |
| dc.identifier.pmid | 35271707 |
| dc.identifier.wos | 000836434600006 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |
